Biogen management check

BIIB · Health Care · Biotechnology · CEO Mr. Viehbacher

Filings as of

48
Management score, ranked 439th of 487 · 52nd of 60 in Health Care1 good · 4 to watch · 1 flaggedStrongest: clean books · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$72Peers$120

    What $100 became since fiscal 2021

    016th
    Detail

    $100 invested at the start of fiscal 2021 grew to $72, against $120 for the peer group the company picked itself.

  • Watch

    Does pay follow performance?

    Pay only loosely tracked returns20212025

    Pay actually paid $100 value, each on its own scale

    5516th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.11 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.8% of net income

    $23.6m pay · $1.3bn net income, FY2025

    0.1%1%3%10%
    2831st
    Detail

    $23.6m of reported pay in fiscal 2025, against $1.3bn of net income.

  • n/a

    Do they own the stock?

    No recent CEO filing
    ——

    Light activity: no buys, $240k sold in six months. 2 of 2 sales ran on pre-arranged 10b5-1 plans.

  • Watch

    Are owners being diluted?

    Share count growing2021 · 150m2025 · 147m

    Diluted shares +0.5% a year; flagged above +2%

    0%10%20%

    Stock pay 2.9% of revenue

    4424th
    Detail

    Diluted shares changed +0.5% a year over the last three fiscal years. Stock-based pay was 2.9% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    5 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Mr. Vounatsos, Mr. Viehbacher

    6038th
    Detail

    CEOs in the pay table: Mr. Vounatsos, Mr. Viehbacher. 5 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 28, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
−$4.5m$13.0m$30.5m$10020212022202320242025$72$120

Pay tied most to Revenue

Other key measuresGrowth Product RevenueTotal RevenueTotal Stockholder ReturnNon-GAAP Earnings Per ShareAchievement of Pipeline Milestones

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Viehbacher$23.6m$27.7m$5.9m$72$120$1.3bn
2024Mr. Viehbacher$24.2m$1.3m$6.4m$62$91$1.6bn
2023Mr. Viehbacher$4.1m−$4.5m$6.3m$106$92$1.2bn
2022Mr. Viehbacher, Mr. Vounatsos$30.5m$27.6m$5.9m$113$89$3.0bn
2021Mr. Vounatsos$17.7m$15.2m$5.8m$98$99$1.6bn

Insiders and the CEO's stakeQuiet

Light activity: no buys, $240k sold in six months. 2 of 2 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldLloyd MinorDirector · 10b5-1 plan$240kAug 4, 2026

Leadership and governance on file

20222023202420252026Leadership 11Votes 6
All 11 filings

Latest shareholder vote results: Jun 10, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $2.5bn returned to owners in buybacks and dividends, 29% of net income, and $1.3bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$1.5bn$3.0bn20212022202320242025Shares150m146m146m146m147m
Show the figures
Fiscal year20212022202320242025
Revenue$11.0bn$10.2bn$9.8bn$9.7bn$9.9bn
Net income$1.6bn$3.0bn$1.2bn$1.6bn$1.3bn
Stock-based pay$238.6m$254.1m$264.2m$291.2m$290.8m
Buybacks$1.8bn$750.0m$0$0—
Dividends—————
Diluted shares150m146m146m146m147m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.